The Rider Institute has launched an Indiegogo campaign to develop DRACOS, which are broad-spectrum antivirals. If it doesn't work, Dr. Todd Rider (Ph.D. from MIT) could enjoy a great career as a charmingly nerdy YouTube star.
Currently there are relatively few prophylactics or therapeutics for viruses, and most that do exist are highly virus- or even strain-specific or have undesirable side effects or other disadvantages. We have developed a radically new, broad-spectrum antiviral therapeutic/prophylactic that has the potential to revolutionize the treatment of viral infections.Our Double-stranded RNA Activated Caspase Oligomerizer (DRACO) approach selectively induces apoptosis (cell suicide) in cells containing viral double-stranded RNA (dsRNA). DRACO should recognize virus-infected cells and rapidly kill those cells without harming uninfected cells, thereby terminating the viral infection while minimizing the impact on the host.
He is asking for $100,000 to fund his research.